Viscosupplementation – Hyaluronic Acid

What Is Viscosupplementation?

Viscosupplementation is a treatment in which hyaluronic acid (HA) — a gel-like substance that occurs naturally in healthy joint fluid — is injected directly into a joint. In a healthy knee or hip, hyaluronic acid acts as a lubricant and shock absorber, allowing the joint to move smoothly. In osteoarthritis, HA degrades and clears from the joint at higher rates than normal, reducing the synovial fluid’s natural viscoelasticity and contributing to cartilage loss and pain.

Viscosupplementation aims to restore this natural cushioning environment — reducing pain, improving mobility, and potentially slowing further cartilage deterioration.

What Joints Can Be Treated?

Viscosupplementation is most commonly used for:

  • Knee — the most studied and most commonly injected joint
  • Hip — effective for appropriate patients, typically performed under ultrasound or fluoroscopic guidance
  • Shoulder — increasingly used for glenohumeral osteoarthritis
  • Other joints — including the ankle, wrist, and temporomandibular joint in select cases

Available Formulations

Multiple FDA-approved hyaluronic acid products are available, differing in molecular weight, source (rooster comb-derived or bacterial fermentation), number of injections required, and cross-linking:

  • Single-injection formulations: Gel-One, Durolane, Monovisc — one injection per treatment cycle
  • Multi-injection formulations: Hyalgan, Supartz, Euflexxa, Orthovisc, Synvisc — typically 3–5 weekly injections per cycle

The choice of formulation depends on patient preference, clinical factors, and insurance coverage where applicable. No single formulation has consistently demonstrated superiority over others in head-to-head studies.

How Viscosupplementation Differs From Other Injections

TreatmentMechanismTypical DurationTissue Effects
CorticosteroidSuppresses inflammationWeeks to monthsMay weaken tissue with repeated use
Hyaluronic AcidRestores joint lubricationMonths to 6+ monthsNeutral to protective
PRPStimulates biological repair6–12+ monthsRegenerative

Viscosupplementation occupies a distinct clinical niche — it is more durable than corticosteroids and carries no tissue-weakening effects, but it is not a regenerative treatment in the way PRP is. For some patients, HA and PRP used together may provide superior outcomes to either alone.

What the Evidence Shows — The Case For Viscosupplementation

  • A 2025 systematic umbrella review of multiple meta-analyses found viscosupplementation provides moderate efficacy in pain relief and functional improvement, particularly in early-to-moderate osteoarthritis
  • The 2024 EUROVISCO Consensus Guidelines — developed by 12 international osteoarthritis experts — specifically recommend HA for patients with mild-to-moderate knee OA (KL grades I–III) who are insufficiently managed with first-line therapies
  • A large double-blind RCT found patients with KL grade II knee OA receiving HA demonstrated statistically significant improvements in pain scores over saline at 26-week follow-up — with less severe disease predicting better response
  • HA injections have been associated with delayed total knee replacement surgery in database analyses of large patient populations
  • HA is safe for repeated use — systematic reviews have found low adverse event rates with repeat injection cycles
  • HA combined with PRP has demonstrated superior outcomes to either treatment alone in multiple studies — particularly at 6 and 12 months — making combination therapy an emerging option for appropriate patients
  • Expert consensus guidelines note HA is particularly appropriate for patients with contraindications to oral anti-inflammatory medications or those seeking to avoid the tissue effects of repeated corticosteroid injections

What the Evidence Shows — The Case for Caution

  • The evidence base for viscosupplementation is genuinely divided at the guideline level — a notable fact patients should understand:
    • AAOS: Cannot recommend HA due to concerns about publication bias in the literature
    • OARSI: Conditional recommendation in favor of HA, particularly for patients who are not surgical candidates
    • ACR/Arthritis Foundation: No recommendation for or against
    • EUROVISCO: Recommends for appropriate patients with mild-to-moderate OA
  • A major 2022 BMJ systematic review and meta-analysis of 24 placebo-controlled trials involving nearly 9,000 patients found HA provided only clinically irrelevant pain reduction compared to placebo in the overall analysis — though subgroup analyses suggested benefit in earlier-stage disease
  • Benefits are most pronounced in mild-to-moderate osteoarthritis — patients with advanced or bone-on-bone disease are unlikely to respond meaningfully
  • Long-term benefits beyond 6 months are variable and not consistently demonstrated across studies
  • Some patients experience a post-injection flare — temporary increased pain and swelling lasting several days — particularly with higher molecular weight formulations

Who Is Most Likely to Benefit?

The evidence consistently points to the following patient profile as most likely to respond:

  • Mild-to-moderate osteoarthritis (Kellgren-Lawrence grades I–III)
  • Normal weight or moderately overweight (BMI under 30 produces better outcomes)
  • Insufficient relief from physical therapy, oral medications, or NSAID use
  • No significant joint malalignment or meniscal pathology
  • Contraindication to or concerns about repeated corticosteroid injections
  • Patients looking to delay joint replacement surgery

Viscosupplementation is generally not recommended for:

  • End-stage bone-on-bone arthritis with complete joint space loss where surgery is clearly indicated
  • Active joint infection
  • Known allergy to hyaluronic acid products or avian proteins (for egg/rooster comb-derived products)

Viscosupplementation and PRP — A Combined Approach

Emerging evidence suggests that combining PRP and HA may outperform either treatment alone. The biological rationale is complementary: PRP delivers growth factors that stimulate tissue repair, while HA restores the mechanical and rheological environment of the joint. Multiple studies have shown that administering PRP first, followed by HA, yields the best outcomes — particularly for sustained pain relief and functional improvement at 6 and 12 months.

This combination approach is worth discussing during your consultation if you are being considered for either treatment.

From a Research & Clinical Perspective

Viscosupplementation has a genuinely mixed evidence base — some high-quality meta-analyses support its use for mild-to-moderate osteoarthritis while others find only clinically irrelevant benefit over placebo. The inconsistency in guideline recommendations reflects this mixed evidence honestly. What the research does suggest consistently is that patient selection matters enormously — earlier-stage disease, lower BMI, and absence of structural instability all predict better response. For patients who fit this profile and are looking for an alternative to repeated corticosteroids or not yet ready for surgery, viscosupplementation remains a reasonable option. Whether this treatment is currently offered at this practice can be confirmed at your consultation — Dr. Murakami will discuss all appropriate treatment options based on your specific clinical picture.

Sources & Further Reading

The following peer-reviewed studies informed the content on this page. Links open in a new tab.

Supporting Evidence

Negative and Limiting Evidence

Combined HA + PRP Evidence

This page was last reviewed March 2026.

Hyaluronic Acid for Your Knees